Journal of Clinical Oncology, Vol 21, Issue 6
(March), 2003: 1147-1154
© 2003 American Society for Clinical Oncology
General Quality of Life 2 Years Following Treatment for Prostate Cancer: What Influences Outcomes? Results From the Prostate Cancer Outcomes Study
David F. Penson,
Ziding Feng,
Alan Kuniyuki,
Dale McClerran,
Peter C. Albertsen,
Dennis Deapen,
Frank Gilliland,
Richard Hoffman,
Robert A. Stephenson,
Arnold L. Potosky,
Janet L. Stanford
From the Section of Urology, VA Puget Sound Health Care System and the Department of Urology, University of Washington, and the Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA; the Division of Urology, University of Connecticut School of Medicine, Farmington, CT; the Department of Preventive Medicine, University of Southern California, Los Angeles, CA; the Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM; the Department of Urology, University of Utah School of Medicine, Salt Lake City, Utah; and the Applied Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD.
Address reprint requests to David F. Penson, MD, MPH, VAPSHCS Section of Urology, 112-UR, 1660 South Columbian Way, Seattle, WA 98108; email: penson{at}u.washington.edu.
Purpose: The goal of this study was to determine the relationship between primary treatment, urinary dysfunction, sexual dysfunction, and general health-related quality of life (HRQOL) in prostate cancer.
Methods: A sample of men with newly diagnosed prostate cancer between 1994 and 1995 was randomly selected from six population-based Surveillance, Epidemiology, and End Results registries. A baseline survey was completed by 2,306 men within 6 to 12 months of diagnosis, and these men also completed a follow-up HRQOL survey 2 years after diagnosis. Logistic regression models were used to determine whether primary treatment, urinary dysfunction, and sexual dysfunction were independently associated with general HRQOL outcomes approximately 2 years after diagnosis as measured by the Medical Outcomes Study 36-item Short Form Health Survey. The magnitude of this effect was estimated using least square means models.
Results: After adjustment for potential confounders, primary treatment was not associated with 2-year general HRQOL outcomes in men with prostate cancer. Urinary function and bother were independently associated with worse general HRQOL in all domains. Sexual function and bother were also independently associated with worse general HRQOL, although the relationship was not as strong as in the urinary domains.
Conclusion: Primary treatment is not associated with 2-year general HRQOL outcomes in prostate cancer. Although both sexual and urinary function and bother are associated with quality of life, men who are more bothered by their urination or impotence are more likely to report worse quality of life. This implies that future research should be directed toward finding ways to improve treatment-related outcomes or help patients better cope with their posttreatment urinary or sexual dysfunction.
Supported by the following contracts from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, to each of the participating institutions: N01-PC-67007, N01-PC-67009, N01-PC-67010, N01-PC-67006, N01-PC-67005, and N01-PC-67000. While this work was completed, Dr. Penson was supported by a Level I Career Development Award from the Health Services Research and Development Service, Department of Veterans Affairs.
This article has been cited by other articles:
|
|
|
|
 
K. Kelly, P. Brader, A. Rein, J. P. Shah, R. J. Wong, Y. Fong, and Z. Gil
Attenuated multimutated herpes simplex virus-1 effectively treats prostate carcinomas with neural invasion while preserving nerve function
FASEB J,
June 1, 2008;
22(6):
1839 - 1848.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Moinpour, K. A. Hayden, J. M. Unger, I. M. Thompson Jr, M. W. Redman, E. D. Canby-Hagino, B. A. Higgins, J. W. Sullivan, D. Lemmon, S. Breslin, et al.
Health-Related Quality of Life Results in Pathologic Stage C Prostate Cancer From a Southwest Oncology Group Trial Comparing Radical Prostatectomy Alone With Radical Prostatectomy Plus Radiation Therapy
J. Clin. Oncol.,
January 1, 2008;
26(1):
112 - 120.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lipscomb, C. C. Gotay, and C. F. Snyder
Patient-reported Outcomes in Cancer: A Review of Recent Research and Policy Initiatives
CA Cancer J Clin,
September 1, 2007;
57(5):
278 - 300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Miller, M. G. Sanda, R. L. Dunn, J. E. Montie, H. Pimentel, H. M. Sandler, W. P. McLaughlin, and J. T. Wei
Long-Term Outcomes Among Localized Prostate Cancer Survivors: Health-Related Quality-of-Life Changes After Radical Prostatectomy, External Radiation, and Brachytherapy
J. Clin. Oncol.,
April 20, 2005;
23(12):
2772 - 2780.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. F. Penson and H. Wessells
Erectile Dysfunction in Diabetic Patients
Diabetes Spectr,
October 1, 2004;
17(4):
225 - 230.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Potosky, W. W. Davis, R. M. Hoffman, J. L. Stanford, R. A. Stephenson, D. F. Penson, and L. C. Harlan
Five-Year Outcomes After Prostatectomy or Radiotherapy for Prostate Cancer: The Prostate Cancer Outcomes Study
J Natl Cancer Inst,
September 15, 2004;
96(18):
1358 - 1367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Vordermark and O. Koelbl
Quality of Life After Treatment for Prostate Cancer: No Difference Between Surgery and Radiotherapy?
J. Clin. Oncol.,
December 15, 2003;
21(24):
4655 - 4655.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. F. Penson and J. L. Stanford
In Reply:
J. Clin. Oncol.,
December 15, 2003;
21(24):
4655 - 4656.
[Full Text]
[PDF]
|
|
|
|
